A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

This trial is testing whether adding itraconazole — an antifungal medication — to standard chemotherapy and radiation treatment before surgery can improve outcomes in patients with esophageal or stomach junction cancer. Lab studies suggest itraconazole may make cancer cells more sensitive to chemo and radiation. **You may be eligible if...** - You have been diagnosed with esophageal cancer (squamous cell or adenocarcinoma) or gastroesophageal junction cancer - Your cancer is operable (removable by surgery) and your surgeon plans to do so - You are planned to receive standard chemotherapy and radiation before surgery - You are in adequate general health (WHO/ECOG performance status 0–2) - Your kidney and liver function are satisfactory **You may NOT be eligible if...** - You have severe heart failure (NYHA Class III or IV) - Your liver tests are more than 3 times the normal upper limit - You have a known allergy to itraconazole - You are pregnant Talk to your doctor to see if this trial is right for you.